Monopar的uPA抗体片段放射性示踪剂在临床前研究中显示出对乳腺癌PET成像的潜力
March 30, 2021 13:35 ET
|
Monopar Therapeutics Inc.
伊利诺伊州维尔梅特, March 31, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（Nasdaq：MNPR）是一家临床阶段的生物制药公司，主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法。该公司今天宣布发表了一项同行评审研究，标题为“对应纤溶酶原激活剂的工程抗体片段用于通过正电子发射断层显像技术对三阴性乳腺癌的快速勾画。”...
Monopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study
March 30, 2021 07:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 30, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates
March 25, 2021 08:00 ET
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Clinical Trial CommencedCamsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021MNPR-101-Conjugate Data Published in European Journal of Cancer WILMETTE,...
Monopar携手经验丰富的Medtech高管，探寻将MNPR-101用作uPAR癌症手术显像剂的潜力
March 02, 2021 07:30 ET
|
Monopar Therapeutics Inc.
伊利诺伊州维尔梅特, March 02, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（纳斯达克股票代码：MNPR）是一家临床阶段生物制药公司，主要从事延长癌症患者寿命或改善其生活质量专有疗法研发，今日宣布与连续医疗科技创业家Andrew...
Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery
March 02, 2021 07:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 02, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Therapeutics to Present at Upcoming Investor Conferences
February 24, 2021 07:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations
February 18, 2021 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
February 16, 2021 07:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Monopar宣布其评估Validive®预防化疗引起口咽癌（OPC）患者重度口腔粘膜炎（SOM）效果的2b/3期（VOICE）试验完成首次患者给药
February 16, 2021 07:30 ET
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（纳斯达克股票代码：MNPR）是一家临床阶段生物制药公司，专注于开发延长癌症患者寿命或提高其生活质量的专利疗法。该公司今天宣布，已在Validive®的2b/3期VOICE（prevention of chemoradiotherapy-induced...
Monopar宣布发表论文展示MNPR-101作为改善膀胱癌手术预后的显像剂的应用潜力
February 11, 2021 08:26 ET
|
Monopar Therapeutics Inc.
伊利诺伊州威尔梅特, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.（Nasdaq：MNPR）是一家临床阶段的生物制药公司，主要专注于开发旨在延长癌症患者寿命并改善其生活质量的专有疗法。该公司今天宣布其一篇同行评议研究的论文在《European Journal of...